drugset / Trial / NCT00209651
Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer
Phase 2
Unknown
40 enrolled
Hokkaido Gastrointestinal Cancer Study Group
Hokkaido University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative colorectal cancer.
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | TS-1 | Small molecule | 80 mg/m2 | Oral |